Sickle Cell Disease in East African Countries: Prevalence, Complications and Management

Main Article Content

Joseph Kawuki
Taha Hussein Musa
Nathan Obore
Shireen Salome Papabathini

Abstract

Sickle cell disease (SCD) is one of the most common life-threatening monogenic disorders affecting millions of people worldwide. The disease has a high prevalence in malaria-endemic tropics, especially in sub-Saharan Africa. Although sickle-cell trait (SCT) offers protective advantage against malaria, it does not apply to homozygous individuals with sickle cell anemia but instead makes them more susceptible to not only malaria but to also other infections, causing a great deal of under-five mortality. Despite the fatal risks and high incidence rates of SCD, little attention is given, in terms of funding, management and surveillance, especially among East African countries. In addition, few works of literature exist, and less has been documented about the disease. This minireview aimed to report the current situation in terms of prevalence, mortality, diagnosis and management of SCD among East African countries; Uganda, Kenya, Tanzania, Rwanda and Burundi.

SCD is characterised by retarded growth, chronic pain attacks and severe organ damage leading to fatal complications. This, coupled with limited resources in East African countries, reduces the survival of SCD patients and most die before five years. SCD is detected through a blood test usually by Haemoglobin electrophoresis, and Hydroxyurea therapy, antibiotics and blood transfusion are used to prevent complications. Early childhood detection through comprehensive newborn screening programmes has been implemented in some countries and is key in the management of the disease.

Keywords:
Prevalence, sickle cell disease, East Africa, management.

Article Details

How to Cite
Kawuki, J., Musa, T., Obore, N., & Papabathini, S. (2019). Sickle Cell Disease in East African Countries: Prevalence, Complications and Management. Journal of Advances in Medicine and Medical Research, 30(8), 1-9. https://doi.org/10.9734/jammr/2019/v30i830220
Section
Minireview Article

References

Kato GJ, Piel FB, Reid CD, Gaston MH, Kwaku OF, Krishnamurti L, et al. Sickle cell disease. Nat. Rev. Dis. Primer; 2018.
(Accessed on 08 April 2019)
Available:https://www.nature.com/articles/nrdp201810#article-info

Azar S, Wong TE. Sickle cell disease: A brief update. Med Clin N Am; 2016.
(Accessed 20 August 2019)
Available:https://pediatrics.aappublications.org/content/137/6/e20160348

Genetics home reference. Sickle Cell Disease; 2019.
(Accessed 06 April 2019)
Available:https://ghr.nlm.nih.gov/condition/sickle-cell-disease.

National heart, lung and blood institute. Sickle cell Disease; 2018.
(Accessed 06 April 2019)
Available: https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease.

Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. The Lancet. 2010; 2018–2031.

Kassim AA, DeBaun MR. Sickle cell disease, vasculopathy and therapeutics. Annu. Rev. Med. 2013;451–466.

Naik RP, Haywood C. Sickle cell trait diagnosis: clinical and social implications. Hematology. 2015;160–167.

Bonham VL, Dover GJ, Brody LC. Screening Student Athletes for Sickle Cell Trait- A Social and Clinical Experiment. N. Engl. J. Med. 2010;997–999.

Benson JM, Therrell BL. History and current status of newborn screening for hemoglobinopathies. Semin. Perinatol. 2010;134–144.

Aaron WB, Arvind V. Does routine urinalysis and chest radiography detect occult bacterial infection in sickle cell patients presenting to the accident and emergency department with painful crisis?. 2005.
(Accessed 12 June 2019)
Available:https://bestbets.org/bets/bet.php?id=1102

Lees CM, Davies S, Dezateux C. Neonatal screening for sickle cell disease. Cochrane Database Syst. Rev; 2000.
(Accessed 20 June 2019)
Available:http://discovery.ucl.ac.uk/1417239

Weatherall D. The inherited disorders of haemoglobin: an increasingly neglected global health burden. Indian J Med Res. 2011;134:493-7.

Tshilolo L, Kafando E, Sawadogo M, Cotton F, Vertongen F, Ferster A. Neonatal screening and clinical care programmes for sickle cell disorders in sub-Saharan Africa: lessons from pilot studies. Public Health. 2008;933-41.

McGann PT. Time to invest in sickle cell anemia as a global health priority. Pediatr. 2016;137:e20160348.

Wastnedge E, Waters D, Patel S, Morrison K, Goh MY, Adeloye D, et al. The global burden of sickle cell disease in children under five years of age: A systematic review and meta-analysis. J. Glob. Health. 2018.
(Accessed 20 July 2019)
Available:https://www.ncbi.nlm.nih.gov/pubmed/30574296.

Roth GA, Abate D, Kalkidan AH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018; 1736–1788.

Regional Committee for Africa, 60. Sickle-Cell Disease: A strategy for the WHO African Region; 2011.
Accessed 09 April 2019
Available:https://apps.who.int/iris/handle/10665/1682

Ndeezi G, Kiyaga C, Hernandez AG, Munube D, Howard TA, Ssewanyana I, et al. Burden of sickle cell trait and disease in the Uganda Sickle Surveillance Study (US3): a cross-sectional study. Lancet Glob. Health. 2016;4(1):e195–e200.

Okwi AL, Byarugaba W, Ndugwa CM, Parkes A, Ocaido M, Tumwine JK. An up-date on the prevalence of sickle cell trait in Eastern and Western Uganda. BMC Hematol. 2010;10:5.
(Accessed 06 April 2019)
Available:https://bmchematol.biomedcentral.com/articles/10.1186/1471-2326-10-5

Lwanira CN, Kironde F, Kaddumukasa M, and Swedberg G. Prevalence of polymorphisms in glucose-6-phosphate dehydrogenase, sickle haemoglobin and nitric oxide synthase genes and their relationship with incidence of uncomplicated malaria in Iganga, Uganda. Malar. J. 2017;16:1.
(Accessed 12 July 2019)
Available:http://malariajournal.biomedcentral.com/articles/10.1186/s12936-017-1970-1.

Mandu K, Tusuubira SK, Mwambi B, Webbo F, Atuhairwe C, Taremwa IM. To test or not: occurrence of sickle cell trait and assessment of the awareness toward its screening among patients attending Magale Health Center IV, Namisindwa & nbsp; District, Eastern Uganda. J. Blood Med. 2018;2018(9): 219–225.

Mpimbaza A, Walakira A, Ndeezi G, Katahoire A, Karamagi C, Nsobya SL, et al. Associations between erythrocyte polymorphisms and risks of uncomplicated and severe malaria in Ugandan children: A case control study. PLOS ONE. 2018; 13(9):e0203229.

Dhabangi A, Idro R, John CC, Dzik WH, Opoka R, Ssenyonga R, et al. Risk factors for recurrent severe anemia among previously transfused children in Uganda: An age-matched case-control study. BMC Pediatr. 2019; 19:27.
(Accessed 20 June 2019)
Available:https://bmcpediatr.biomedcentral.com/articles/10.1186/s12887-019-1398-6

Komba AN, Makani J, Sadarangani M, Tolu AA, Berkley JA, Newton CRJ, et al. Malaria as a Cause of Morbidity and Mortality in Children with Homozygous Sickle Cell Disease on the Coast of Kenya. Clin. Infect. Dis. 2009;49(2):216–222.

Suchdev PS, Williams TN, Sadumah I, Sullivan KM, Foote EM, Oremo J, et al. Determinants of Anemia among Preschool Children in Rural, Western Kenya. Am. J. Trop. Med. Hyg. 2013; 88(4):757–764.

Byrd KA, Williams TN, Lin A, Pickering AJ, Arnold BF, Arnold CD, et al. Sickle cell and α+-Thalassemia traits influence the association between Ferritin and Hepcidin in rural Kenyan children aged 14–26 Months. J. Nutr. 2018;148(12):903–1910.

Hau DK, Chami N, Duncan A, Smart LR, Hokororo A, Kayange NM, et al. Post-hospital mortality in children aged 2-12 years in Tanzania: A prospective cohort study. PLOS ONE. 2018;13(8):e0202334.

Ambrose EE, Makani J, Chami N, Masoza T, Kabyemera R, Peck RN, et al. High birth prevalence of sickle cell disease in Northwestern Tanzania. Pediatr. Blood Cancer. 2017;65(1):e26735

Muganyizi PS, Kidanto H. Sickle Cell Disease in Pregnancy: Trend and Pregnancy Outcomes at a Tertiary Hospital in Tanzania. PLoS ONE. 2013;8(2): e56541.

Kamugisha E, Manyama M, Rambau P, Mazigo H, Mshana S, Masesa Z. Prevalence of sickle cell, malaria and glucose-6-phosphate dehydrogenase deficiency among primary school children in Nyamagana District, Mwanza-Tanzania. Tanzan. Med. J. 2011;25:1.
(Accessed 12 April 2019)
Available:http://www.ajol.info/index.php/tmj/article/view/70954

Gahutu JB, Musemakweri A, Harms G, Mockenhaupt FP. Prevalence of classic erythrocyte polymorphisms among 749 children in southern highland Rwanda. Trans. R. Soc. Trop. Med. Hyg. 2012;106 (1):63–65.

Mutesa L, Uwineza A, Hellin AC, Muvunyi CM, Vanbellinghen JF, Umurerwa L, et al. A survey of genetic diseases in Rwanda. Rwanda Med. J. 2010;68:3.
(Accessed 12 April 2019)
Available:http://www.bioline.org.br/pdf?rw10015

Mayo clinic staff. Sickle cell anemia - Diagnosis and Treatment; 2019.
(Accessed 06 April 2019)
Available:https://www.mayoclinic.org/diseases-conditions/sickle-cell-anemia/diagnosis-treatment/drc-20355882.

Brewin J, Howard J. Sickle cell disease: An update on management. Paediatr. Child Health. 2017;506–510.

Gluckman E, Cappelli B, Bernaudin F, Labopin M, Volt F, Carreras J, et al. Sickle cell disease: An international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;1548–1556.

Shenoy S. Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions. Ther. Adv. Hematol. 2013;335–344.

McGann PT, Nero AC, Ware RE. Current management of sickle cell anemia. Cold Spring Harb. Perspect. Med. 2013; a011817–a011817.

Joshua FJ, Elliott PV, Michael DR. Overview of the management and prognosis of sickle cell disease; 2018.
(Accessed 10 April 2019)
Available:https://www.uptodate.com/contents/overview-of-the-management-and-prognosis-of-sickle-cell-disease.

Ademola AS. Management of sickle cell disease: A review for physician education in Nigeria (Sub-Saharan Africa). Anemia. 2015; 2015(791498).
(Accessed 08 April 2019)
Available:https://www.hindawi.com/journals/anemia/2015/791498/.

Oniyangi O, Omari A. Malaria chemoprophylaxis in sickle cell disease. Cochrane Database Syst. Rev. 2006;13(4): CD003489.

Yawn BP, Buchanan GR, Araba NA, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;1033–1048.